Design and optimization of hybrid of 2,4-diaminopyrimidine and arylthiazole scaffold as anticancer cell proliferation and migration agents.
Design and optimization of hybrid of 2,4-diaminopyrimidine and arylthiazole scaffold as anticancer cell proliferation and migration agents.
复制标题
DOI：
10.1016/j.ejmech.2015.04.027
复制
发表时间：
2015-05
影响因子：
6.7
通讯作者：
Wenbo Zhou;Anling Huang;Yong Zhang;Q. Lin;Weikai Guo;Zihua You;Zhengfang Yi;Mingyao Liu;Yihua Chen
中科院分区：
文献类型：
--
作者：
Wenbo Zhou;Anling Huang;Yong Zhang;Q. Lin;Weikai Guo;Zihua You;Zhengfang Yi;Mingyao Liu;Yihua Chen
Therapeutics of metastatic or triple-negative breast cancer are still challenging in clinical. Herein we demonstrated the design and optimization of a series of hybrid of 2,4-diaminopyrimidine and arylthiazole derivatives for their anti-proliferative properties against two breast cancer cell lines (MCF-7 as human breast cancer and MDA-MB-231 as triple-negative breast cancer). More importantly, some of those compounds with potent antiproliferative activities also indicated excellent inhibitory activities against MDA-MB-231 cell migration. These results suggested that the new series of hybridation of aryl-thiazoles and aminopyrimidines could be identified and developed as novel highly potential anticancer agents against the triple-negative breast cancer as well as metastatic one in the future.
